Tamoxifen enhances romidepsin-induced apoptosis in T-cell malignant cells via activation of FOXO1 signaling pathway

References

• Vose J, Armitage J, Weisenburger D, International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124–4130.
   PubMed Web of Science ®Google Scholar
• Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;126(7):833–841.
   PubMed Web of Science ®Google Scholar
• Szczepanski T, van der Velden VH, Waanders E, et al. Late recurrence of childhood T-cell acute lymphoblastic leukemia frequently represents a second leukemia rather than a relapse: first evidence for genetic predisposition. J Clin Oncol. 2011;29(12):1643–1649.
   PubMed Web of Science ®Google Scholar
• Weisenburger DD, Savage KJ, Harris NL, et al.; for the International Peripheral T-cell Lymphoma Project. Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project. Blood. 2011;117(12):3402–3408.
   PubMed Web of Science ®Google Scholar
• Savage KJ. Therapies for peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program. 2011;2011:515–524.
   PubMed Web of Science ®Google Scholar
• Ma H, Davarifar A, Amengual JE. The future of combination therapies for peripheral T cell lymphoma (PTCL). Curr Hematol Malig Rep. 2018;13(1):13–24.
   PubMed Web of Science ®Google Scholar
• Petrich A, Nabhan C. Use of class I histone deacetylase inhibitor romidepsin in combination regimens. Leuk Lymphoma. 2016;57(8):1755–1765.
   PubMed Web of Science ®Google Scholar
• Suraweera A, O'Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: achieving the full therapeutic potential of HDACi. Front Oncol. 2018;8:92.
   PubMed Web of Science ®Google Scholar
• Mandlekar S, Kong ANT. Mechanisms of tamoxifen-induced apoptosis. Apoptosis. 2001;6(6):469–477.
   PubMed Web of Science ®Google Scholar
• Avgeropoulos NG, Batchelor TT. New treatment strategies for malignant glioma. Oncologist. 1999;4(3):209–224.
   PubMedGoogle Scholar
• Emi N, Abe A, Kasai M, et al. CD4- and CD56-positive T-cell line, MTA, established from natural killer-like T-cell leukemia/lymphoma. Int J Hematol. 1999;69(3):180–185.
   PubMed Web of Science ®Google Scholar
• Kasukabe T, Okabe-Kado J, Kato N, et al. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res. 2005;7(6):R1097–1110.
   PubMed Web of Science ®Google Scholar
• Buege JA, Aust SD. Microsomal lipid peroxidation. Methods Enzymol. 1978;52:302–310.
   PubMedGoogle Scholar
• Atkinson J, Harroun T, Wassall SR, et al. The location and behavior of alpha-tocopherol in membranes. Mol Nutr Food Res. 2010;54(5):641–651.
   PubMed Web of Science ®Google Scholar
• Sandor V, Bakke S, Robey RW, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176) in patients with refractory neoplasms. Clin Cancer Res. 2002;8(3):718–728.
   PubMed Web of Science ®Google Scholar
• Pluchino LA, Choudhary S, Wang H-CR. Reactive oxygen species-mediated synergistic and preferential induction of cell death and reduction of clonogenic resistance in breast cancer cells by combined cisplatin and FK228. Cancer Lett. 2016;381(1):124–132.
   PubMed Web of Science ®Google Scholar
• Makena MR, Koneru B, Nguyen TH, et al. Reactive oxygen species-mediated synergism of fenretinide and romidepsin in preclinical models of T-cell lymphoid malignancies. Mol Cancer Ther. 2017;16(4):649–661.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Sakamoto K. Forkhead transcription factor FOXO subfamily is essential for reactive oxygen species-induced apoptosis. Mol Cell Endocrinol. 2008;281(1-2):47–55.
   PubMed Web of Science ®Google Scholar
• Fu Z, Tindall DJ. FOXOs, cancer and regulation of apoptosis. Oncogene. 2008;27(16):2312–2319.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou Y, Graves DT. FOXO transcription factors: their clinical significance and regulation. Biomed Res Int. 2014;2014:925350.
   PubMed Web of Science ®Google Scholar
• Pramanik KC, Fofaria NM, Gupta P, et al. CBP-mediated FOXO-1 acetylation inhibits pancreatic tumor growth by targeting SirT. Mol Cancer Ther. 2014;13(3):687–698.
   PubMed Web of Science ®Google Scholar
• Dhordain P, Albagli O, Lin RJ, et al. Corepressor SMRT binds the BTB/POZ repressing domain of the LAZ3/BCL6 oncoprotein. Proc Natl Acad Sci USA. 1997;94(20):10762–10767.
   PubMed Web of Science ®Google Scholar
• David G, Alland L, Hong S-H, et al. Histone deacetylase associated with mSin3A mediates repression by the acute promyelocytic leukemia-associated PLZF protein. Oncogene. 1998;16(19):2549–2556.
   PubMed Web of Science ®Google Scholar
• Bereshchenko OR, Gu W, Dalla-Favera R. Acetylation inactivates the transcriptional repressor BCL6. Nat Genet. 2002;32(4):606–613.
   PubMed Web of Science ®Google Scholar
• Cortiguera MG, Garcia-Gaipo L, Wagner SD, et al. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells. Sci Rep. 2019;9(1):16495.
   PubMedGoogle Scholar
• Fotoohi AK, Karim H, Lafolie P, et al. Pronounced interindividual but not intraindividual variation in tamoxifen and metabolite levels in plasma during adjuvant treatment of women with early breast cancer. Ther Drug Monit. 2016;38(2):239–245.
   PubMed Web of Science ®Google Scholar
• Berman E, McBride M, Lin S, et al. Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. Leukemia. 1995;9(10):1631–1637.
   PubMed Web of Science ®Google Scholar